118 related articles for article (PubMed ID: 11263375)
1. Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia.
Ni J; Chen G; Shen Z; Li X; Liu H; Huang Y; Fang Z; Chen S; Wang Z; Chen Z
Chin Med J (Engl); 1998 Dec; 111(12):1107-10. PubMed ID: 11263375
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia].
Ni J; Chen G; Shen Z; Li X; Liu H; Huang Y; Fang Z; Chen S; Wang Z; Chen L
Zhonghua Xue Ye Xue Za Zhi; 1997 May; 18(5):250-3. PubMed ID: 15622757
[TBL] [Abstract][Full Text] [Related]
3. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.
Shen ZX; Chen GQ; Ni JH; Li XS; Xiong SM; Qiu QY; Zhu J; Tang W; Sun GL; Yang KQ; Chen Y; Zhou L; Fang ZW; Wang YT; Ma J; Zhang P; Zhang TD; Chen SJ; Chen Z; Wang ZY
Blood; 1997 May; 89(9):3354-60. PubMed ID: 9129042
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide.
Fujisawa S; Ohno R; Shigeno K; Sahara N; Nakamura S; Naito K; Kobayashi M; Shinjo K; Takeshita A; Suzuki Y; Hashimoto H; Kinoshita K; Shimoya M; Kaise T; Ohnishi K
Cancer Chemother Pharmacol; 2007 Mar; 59(4):485-93. PubMed ID: 16937107
[TBL] [Abstract][Full Text] [Related]
5. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
[TBL] [Abstract][Full Text] [Related]
6. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Wang Z; Zhou J; Lu X; Gong Z; Le XC
Chem Res Toxicol; 2004 Jan; 17(1):95-103. PubMed ID: 14727923
[TBL] [Abstract][Full Text] [Related]
7. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.
Zhang P
J Biol Regul Homeost Agents; 1999; 13(4):195-200. PubMed ID: 10703942
[TBL] [Abstract][Full Text] [Related]
8. Significance of intracellular arsenic trioxide for therapeutic response in acute promyelocytic leukemia.
Sahu GR; Jena RK
Am J Hematol; 2005 Feb; 78(2):113-6. PubMed ID: 15682419
[TBL] [Abstract][Full Text] [Related]
9. [A clinical pharmacokinetic study of multi-dose oral tetra-arsenic tetra-sulfide combination therapy in acute promyelocytic leukemia].
Wang FR; Lou YQ; Lu DP
Zhonghua Nei Ke Za Zhi; 2005 Oct; 44(10):730-3. PubMed ID: 16255875
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
Kwong YL; Au WY; Chim CS; Pang A; Suen C; Liang R
Am J Hematol; 2001 Apr; 66(4):274-9. PubMed ID: 11279639
[TBL] [Abstract][Full Text] [Related]
11. Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies.
Kumana CR; Au WY; Lee NS; Kou M; Mak RW; Lam CW; Kwong YL
Eur J Clin Pharmacol; 2002 Nov; 58(8):521-6. PubMed ID: 12451429
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow necrosis in a patient with acute promyelocytic leukemia during re-induction therapy with arsenic trioxide.
Ishitsuka K; Shirahashi A; Iwao Y; Shishime M; Takamatsu Y; Takatsuka Y; Utsunomiya A; Suzumiya J; Hara S; Tamura K
Eur J Haematol; 2004 Apr; 72(4):280-4. PubMed ID: 15089767
[TBL] [Abstract][Full Text] [Related]
13. Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage.
Shen Y; Shen ZX; Yan H; Chen J; Zeng XY; Li JM; Li XS; Wu W; Xiong SM; Zhao WL; Tang W; Wu F; Liu YF; Niu C; Wang ZY; Chen SJ; Chen Z
Leukemia; 2001 May; 15(5):735-41. PubMed ID: 11368433
[TBL] [Abstract][Full Text] [Related]
14. Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment.
Zhao W; Wang X; Guo W; Qu B; Wang H; Shen Z; Chen Z; Wang Z
Chin Med J (Engl); 2000 Mar; 113(3):236-40. PubMed ID: 11775254
[TBL] [Abstract][Full Text] [Related]
15. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
Lazo G; Kantarjian H; Estey E; Thomas D; O'Brien S; Cortes J
Cancer; 2003 May; 97(9):2218-24. PubMed ID: 12712474
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of 65 Chinese children with acute promyelocytic leukemia: a single center experience.
Zhang L; Zhao H; Zhu X; Chen Y; Zou Y; Chen X
Pediatr Blood Cancer; 2008 Aug; 51(2):210-5. PubMed ID: 18428427
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide: safety issues and their management.
Au WY; Kwong YL
Acta Pharmacol Sin; 2008 Mar; 29(3):296-304. PubMed ID: 18298894
[TBL] [Abstract][Full Text] [Related]
18. Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue-selective.
Lin CJ; Wu MH; Hsueh YM; Sun SS; Cheng AL
Cancer Chemother Pharmacol; 2005 Feb; 55(2):170-8. PubMed ID: 15322825
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.
Carmosino I; Latagliata R; Avvisati G; Breccia M; Finolezzi E; Lo Coco F; Petti MC
Haematologica; 2004 May; 89(5):615-7. PubMed ID: 15136230
[TBL] [Abstract][Full Text] [Related]
20. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
Barbey JT; Pezzullo JC; Soignet SL
J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
